Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. 4d Pharma

Evaluate

March 08, 2023

The ink dries on the blank cheque craze

As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?

Thumbnail
July 12, 2021

Spac listings slow as the hunt for deals continues

Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.

Article image
Vantage logo
February 26, 2021

A Spac makes it happen for 4D Pharma

The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.

Article image
Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.

Article image
Vantage logo
October 15, 2020

SITC 2020 – embargo snafu triggers the first movers

The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.

Article image
Vantage logo
August 11, 2020

Seres brings the microbiome back to life

Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.

Article image
Vantage logo
April 27, 2020

Kevzara's Covid-19 setback shows need for hard evidence

As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.

Article image
Vantage logo
June 07, 2019

The Woodford snowball gathers pace

Article image
Vantage logo
July 10, 2017

Strong small cap performance drives second-quarter gains

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up